Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:15986373rdf:typepubmed:Citationlld:pubmed
pubmed-article:15986373lifeskim:mentionsumls-concept:C0087111lld:lifeskim
pubmed-article:15986373lifeskim:mentionsumls-concept:C0754728lld:lifeskim
pubmed-article:15986373lifeskim:mentionsumls-concept:C0949691lld:lifeskim
pubmed-article:15986373lifeskim:mentionsumls-concept:C1411976lld:lifeskim
pubmed-article:15986373lifeskim:mentionsumls-concept:C1456820lld:lifeskim
pubmed-article:15986373lifeskim:mentionsumls-concept:C0205276lld:lifeskim
pubmed-article:15986373lifeskim:mentionsumls-concept:C0205217lld:lifeskim
pubmed-article:15986373lifeskim:mentionsumls-concept:C0017262lld:lifeskim
pubmed-article:15986373lifeskim:mentionsumls-concept:C0332206lld:lifeskim
pubmed-article:15986373lifeskim:mentionsumls-concept:C0205373lld:lifeskim
pubmed-article:15986373lifeskim:mentionsumls-concept:C2911684lld:lifeskim
pubmed-article:15986373lifeskim:mentionsumls-concept:C0185117lld:lifeskim
pubmed-article:15986373pubmed:issue7lld:pubmed
pubmed-article:15986373pubmed:dateCreated2005-7-4lld:pubmed
pubmed-article:15986373pubmed:abstractTextAbnormal host defense against pathogens has been implicated in the pathogenesis of spondylarthropathy (SpA), a disease characterized by abundant synovial infiltration with innate immune cells. Given the role of Toll-like receptors (TLRs) in activation of innate inflammation and the occurrence of TLR-dependent infections after tumor necrosis factor alpha (TNFalpha) blockade treatment, the present study was undertaken to analyze TLRs and their modulation by TNFalpha blockade in SpA.lld:pubmed
pubmed-article:15986373pubmed:languageenglld:pubmed
pubmed-article:15986373pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15986373pubmed:citationSubsetAIMlld:pubmed
pubmed-article:15986373pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15986373pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15986373pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15986373pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15986373pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15986373pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15986373pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15986373pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15986373pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15986373pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15986373pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15986373pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15986373pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15986373pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15986373pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15986373pubmed:statusMEDLINElld:pubmed
pubmed-article:15986373pubmed:monthJullld:pubmed
pubmed-article:15986373pubmed:issn0004-3591lld:pubmed
pubmed-article:15986373pubmed:authorpubmed-author:BaetenDominiq...lld:pubmed
pubmed-article:15986373pubmed:authorpubmed-author:KruithofElliElld:pubmed
pubmed-article:15986373pubmed:authorpubmed-author:VeysEric MEMlld:pubmed
pubmed-article:15986373pubmed:authorpubmed-author:De...lld:pubmed
pubmed-article:15986373pubmed:authorpubmed-author:De RyckeLeenLlld:pubmed
pubmed-article:15986373pubmed:authorpubmed-author:VandoorenBern...lld:pubmed
pubmed-article:15986373pubmed:issnTypePrintlld:pubmed
pubmed-article:15986373pubmed:volume52lld:pubmed
pubmed-article:15986373pubmed:ownerNLMlld:pubmed
pubmed-article:15986373pubmed:authorsCompleteYlld:pubmed
pubmed-article:15986373pubmed:pagination2146-58lld:pubmed
pubmed-article:15986373pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:15986373pubmed:meshHeadingpubmed-meshheading:15986373...lld:pubmed
pubmed-article:15986373pubmed:meshHeadingpubmed-meshheading:15986373...lld:pubmed
pubmed-article:15986373pubmed:meshHeadingpubmed-meshheading:15986373...lld:pubmed
pubmed-article:15986373pubmed:meshHeadingpubmed-meshheading:15986373...lld:pubmed
pubmed-article:15986373pubmed:meshHeadingpubmed-meshheading:15986373...lld:pubmed
pubmed-article:15986373pubmed:meshHeadingpubmed-meshheading:15986373...lld:pubmed
pubmed-article:15986373pubmed:meshHeadingpubmed-meshheading:15986373...lld:pubmed
pubmed-article:15986373pubmed:meshHeadingpubmed-meshheading:15986373...lld:pubmed
pubmed-article:15986373pubmed:meshHeadingpubmed-meshheading:15986373...lld:pubmed
pubmed-article:15986373pubmed:meshHeadingpubmed-meshheading:15986373...lld:pubmed
pubmed-article:15986373pubmed:meshHeadingpubmed-meshheading:15986373...lld:pubmed
pubmed-article:15986373pubmed:meshHeadingpubmed-meshheading:15986373...lld:pubmed
pubmed-article:15986373pubmed:meshHeadingpubmed-meshheading:15986373...lld:pubmed
pubmed-article:15986373pubmed:meshHeadingpubmed-meshheading:15986373...lld:pubmed
pubmed-article:15986373pubmed:meshHeadingpubmed-meshheading:15986373...lld:pubmed
pubmed-article:15986373pubmed:meshHeadingpubmed-meshheading:15986373...lld:pubmed
pubmed-article:15986373pubmed:meshHeadingpubmed-meshheading:15986373...lld:pubmed
pubmed-article:15986373pubmed:meshHeadingpubmed-meshheading:15986373...lld:pubmed
pubmed-article:15986373pubmed:meshHeadingpubmed-meshheading:15986373...lld:pubmed
pubmed-article:15986373pubmed:meshHeadingpubmed-meshheading:15986373...lld:pubmed
pubmed-article:15986373pubmed:meshHeadingpubmed-meshheading:15986373...lld:pubmed
pubmed-article:15986373pubmed:meshHeadingpubmed-meshheading:15986373...lld:pubmed
pubmed-article:15986373pubmed:meshHeadingpubmed-meshheading:15986373...lld:pubmed
pubmed-article:15986373pubmed:meshHeadingpubmed-meshheading:15986373...lld:pubmed
pubmed-article:15986373pubmed:meshHeadingpubmed-meshheading:15986373...lld:pubmed
pubmed-article:15986373pubmed:meshHeadingpubmed-meshheading:15986373...lld:pubmed
pubmed-article:15986373pubmed:meshHeadingpubmed-meshheading:15986373...lld:pubmed
pubmed-article:15986373pubmed:meshHeadingpubmed-meshheading:15986373...lld:pubmed
pubmed-article:15986373pubmed:year2005lld:pubmed
pubmed-article:15986373pubmed:articleTitleTumor necrosis factor alpha blockade treatment down-modulates the increased systemic and local expression of Toll-like receptor 2 and Toll-like receptor 4 in spondylarthropathy.lld:pubmed
pubmed-article:15986373pubmed:affiliationGhent University Hospital, Ghent, Belgium.lld:pubmed
pubmed-article:15986373pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:15986373pubmed:publicationTypeClinical Triallld:pubmed
pubmed-article:15986373pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:15986373lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:15986373lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:15986373lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:15986373lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:15986373lld:pubmed